Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Jul 29, 2021 8:39 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea

July 26, 2021

- GC Pharma to lead development and commercialization in South Korea - Mirum seeks to expand global availability of maralixibat in rare liver diseases FOSTER CITY, Calif. & YONGIN, South Korea --(BUSINESS WIRE)--Jul. 26, 2021-- Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 12, 2021

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jul. 12, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 12, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of common stock to

Mirum Pharmaceuticals to Present at Piper Sandler’s Virtual EASL Takeaway Day

June 24, 2021

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 24, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that it will participate in Piper Sandler’s Virtual European Association for the Study of the Liver (EASL) Takeaway Day on Monday, June 28, 2021 , at

Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021

June 23, 2021

- Data from five years of treatment with maralixibat reinforces safety and tolerability in patients with Alagille syndrome. - Intrahepatic cholestasis of pregnancy patient-reported data demonstrates significant burden of disease and underscores urgent need for new treatment options.

Events

Piper Sandler Virtual EASL Takeaway Day

Jun 28, 2021 at 2:00 PM EDT

EASL International Liver Congress 2021

Jun 23 - Jun 26, 2021

Raymond James 2021 Human Health Innovation Conference

Jun 21 - Jun 23, 2021

Investor Relations

Investor Relations

Corporate Profile

Header Menu